Lifeboat Foundation

Dr. Aubrey de Grey from the SENS Research Foundation was kind enough to talk in support of CellAge and their campaign on Lifespan.io

We are developing tools to help researchers accurately target and remove dysfunctional cells in the body that have entered a state called “senescence”, and thereby assist in restoring it to youthful functionality. Please subscribe, share, and fund our campaign today! ►Campaign Link: https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/ ►Subscribe: https://www.youtube.com/user/LifespanIO?sub_confirmation=1

Continue reading “CellAge: Dr. Aubrey de Grey Endorsement Video” »

Cellular senescence is a complicated process but here it is explained in a simple infographic. The removal of senescent cells (senolytics) is a very hot topic right now and it represents the arrival of the first of the SENS therapies.

CellAge is one of the companies engaged in senolytic research and they are running a campaign on Lifespan.io if you would like to learn more about them.

https://www.lifespan.io/campaigns/cellage-targeting-senescen…c-biology/

Continue reading “Senescent cells accumulate with age and gradually poison their neighboring cells and secrete signals that shut down your stem cells and reduce your ability to regenerate tissue” »

By removing senescent cells from culture prior to transplant.

Designing synthetic promoters for safe and precise targeting of dysfunctional “senescent” cells, with the aim of developing senolytic gene therapies to remove them.

Lilly announced today that CYRAMZA® (ramucirumab) has been approved by the Singapore Health Sciences Authority to treat people with advanced gastric cancer, whose cancer has progressed after prior chemotherapy. First country in ASEAN to approve the new biologic therapy that extends survival in patients with advanced stomach cancer after prior chemotherapy

CYRAMZA^® (ramucirumab) is now available to Singaporeans living with advanced gastric cancer. The drug gained approval by Singapore’s Health Science’s Authority (HSA) earlier this year, marking the first regulatory approval in ASEAN. CYRAMZA is already available to patients in Japan, Korea, Taiwan and Hong Kong.

Now that’s an idea; education for systems. I can see the online university advertisements now showing an autonomous car beeping and flashing its lights over the enjoyment of graduating.

What if I told you to tie your shoes, but you had no laces? Or to cook dinner, but you had no pots or pans.

There are certain tools we need to succeed, which we often don’t have access to or are held back by a gatekeeper.

Continue reading “Why Machines Should Go To The University of Google, School of Artificial Intelligence” »

Nice write on polymeric coatings as a material option consider when developing implants replicating a natural electrode charge without creating damage or disruptions. Author proposes such materials could be leveraged beyond their use today and expanded to include BMI implants. Definitely, will take a closer look at.

Jeff Hendricks Biotectix outlines how polymeric coatings can help improve the performance of medical and consumer electronic devices.

Excellent. Now, the question is “has Microsoft seen this?” as they are working on solving Diabetes too as part of their Synbio program that has already shown us their DNA Data Storage.

People with type 1 diabetes must inject themselves with insulin multiple times per day. This is because their immune system has destroyed cells in the pancreas that secrete insulin to maintain a healthy blood glucose level.

A team of bioengineers now report a possible alternative to such injections. The researchers engineered human kidney cells to act like pancreatic β cells, namely to sense blood glucose levels and produce insulin accordingly (Science 2016, DOI: 10.1126/science.aaf4006). When implanted in mice with type 1 diabetes, the cells prevent high blood glucose levels, also known as hyperglycemia.

Continue reading “Potential diabetes therapy: Engineered cells that control blood sugar” »

Nice.

Chronic pain is thought to involve the long-lasting strengthening of synapses, akin to what happens during the formation of new memories. This phenomenon, known as long-term potentiation (LTP), is triggered when neurons on both sides of a synapse are active at the same time. But now, Jürgen Sandkühler, Medical University of Vienna, Austria, and colleagues provide evidence that LTP in nociceptive circuits arises in a different way.

By simultaneously activating two types of glial cells―astrocytes and microglia―the researchers were able to produce LTP at synapses that connect peripheral C-fibers and lamina I neurons in the dorsal horn spinal cord. They also showed that with high-frequency stimulation of C-fibers, glial cells strengthen active and inactive synapses through their release of the NMDA receptor co-agonist D-serine and the cytokine tumor necrosis factor (TNF). Moreover, these molecules traveled to distant synapses, perhaps explaining why pain hypersensitivity can develop in areas surrounding or far away from an injury.

Continue reading “A New Form of Synaptic Plasticity in Pain Pathways” »

AI joins the fight against Leukemia.